Key facts
- Spark Biomedical’s last known valuation is $66.0M (May 2023).
- It has raised $34.6M across 1 recorded rounds; the latest was Early Stage VC ($16.2M) in Mar 2023.
- Notable investors include Capital Factory, United States Department of War, National Institutes of Health, Houston Angel Network, National Institute on Drug Abuse (NIDA) — 12 tracked in total.
- Spark Biomedical has filed 1 Form D with the SEC, most recently May 2023 ($16.2M sold to 127 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Spark Biomedical
Funding rounds
1 roundsAbout Spark Biomedical
Developer of wearable neurostimulation devices designed to offer opioid withdrawal relief. The company's devices use transcutaneous auricular neurostimulation to stimulate nerves on and around the ear to overcome withdrawal, heal from addiction, and achieve a better quality of life, enabling patients with a non-pharmaceutical approach and long-term recovery support.
- Sector
- Healthcare
- HQ
- Dallas, TX, United States
- Founded
- 2018
- Employees
- 30
- Website
- sparkbiomedical.com/
- Ownership
- Privately Held (backing)
Spark Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spark Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spark Biomedical in its N-PORT filings yet. We sweep new filings monthly.